New short blogpost!
I wrote a round up of cancer research news from ASCO2026:
- Daraxonrasib, the breakthrough pancreatic cancer drug
- Big 7-year results of lorlatinib for ALK+ lung cancers
– Talazoparib, a prostate cancer drug that cut the risk of progression by half
and much more. Read here:
New short blogpost!
I wrote a round up of cancer research news from ASCO2026:
- Daraxonrasib, the breakthrough pancreatic cancer drug
- Big 7-year results of lorlatinib for ALK+ lung cancers
– Talazoparib, a prostate cancer drug that cut the risk of progression by half
and much more. Read here:
Also surprised it has an H5N1 test.
At the back it says, if the result is positive for H5N1 but not flu A, it's a false positive.
But if it's positive for both, you must immediately go to hospital for confirmation.
Wow, spotted at a local grocery store in Hong Kong!
I've never seen a 10 in 1 rapid test before.
Claude Fable's "biosecurity" flags are incredibly restrictive.
This model is going to be almost useless for me.
Remember that recent paper claiming to show that "ideological bias" determined the results obtained by immigration policy research teams?
A careful, open-code reanalysis by @kauspurg.bsky.social & Josef Brüderl finds that the result arises from a coding error. —> doi.org/10.31222/osf...
Me reading the abstract: Well, 'coding error' is a bit strong, isn't it, they just disagreed on some variable coding.
Me getting to p. 3: Oh, OOOHHH, OH NO!!!!
🚨 A few months ago, a paper published in Science reported that “LLM adoption is associated with a large increase in researchers’ scientific output.”
In a comment released today, we show that the reported effects are driven by a methodological issue in the empirical design. arxiv.org/abs/2605.17979
